Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
[Lung abscess: Diagnosis and management].
Feki W, Ketata W, Bahloul N, Ayadi H, Yangui I, Kammoun S.
Rev Mal Respir. 2019 Jun;36(6):707-719. doi: 10.1016/j.rmr.2018.07.010. Epub 2019 Jun 13.
Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F, Ma W, Li W, Ni H, Gao G, Chen X, Zhang J, Shi J.
BMC Cancer. 2018 Oct 23;18(1):1033. doi: 10.1186/s12885-018-4938-9.
Improved Diagnostic Criteria for Apical Hypertrophic Cardiomyopathy.
Hughes RK, Shiwani H, Rosmini S, Augusto JB, Burke L, Jiang Y, Pierce I, Joy G, Castelletti S, Orini M, Kellman P, Xue H, Lopes LR, Mohiddin S, Treibel T, Manisty C, Captur G, Davies R, Moon JC.
JACC Cardiovasc Imaging. 2024 May;17(5):501-512. doi: 10.1016/j.jcmg.2023.07.012. Epub 2023 Oct 11.
Cavity Wall Thickness in Solitary Cavitary Lung Adenocarcinomas Is a Prognostic Indicator.
Watanabe Y, Kusumoto M, Yoshida A, Shiraishi K, Suzuki K, Watanabe SI, Tsuta K.
Ann Thorac Surg. 2016 Dec;102(6):1863-1871. doi: 10.1016/j.athoracsur.2016.03.121. Epub 2016 Sep 20.
Solitary cavities of the lung: diagnostic implications of cavity wall thickness.
Woodring JH, Fried AM, Chuang VP.
AJR Am J Roentgenol. 1980 Dec;135(6):1269-71. doi: 10.2214/ajr.135.6.1269.
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.
Vissing CR, Axelsson Raja A, Day SM, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Bundgaard H, Orav EJ, Ho CY; Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators.
JAMA Cardiol. 2023 Nov 1;8(11):1083-1088. doi: 10.1001/jamacardio.2023.2808.
Right Ventricular Hypertrophy.
Bhattacharya PT, Shams P, Ellison MB.
2024 Mar 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry.
Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, Pereira AC, Wittekind SG, Helms A, Saberi S, Jacoby D, Ware JS, Colan SD, Semsarian C, Ingles J, Lakdawala NK, Ho CY; SHaRe Investigators.
Circulation. 2020 Apr 28;141(17):1371-1383. doi: 10.1161/CIRCULATIONAHA.119.044366. Epub 2020 Mar 31.
Cavitary pulmonary metastases.
Chaudhuri MR.
Thorax. 1970 May;25(3):375-81. doi: 10.1136/thx.25.3.375.
Ominous lung cavity "Tambourine sign".
Verma R, Bhalla AS, Goyal A, Jain D, Loganathan N, Guleria R.
World J Clin Cases. 2017 Apr 16;5(4):153-158. doi: 10.12998/wjcc.v5.i4.153.
